February 2, 2026 — Leads & Copy —
AstraZeneca’s ordinary shares began trading on the New York Stock Exchange (NYSE) today. This move enables more U.S. investors to participate in the company’s growth. The trading of AstraZeneca ordinary shares is now aligned across the NYSE, the London Stock Exchange (LSE), and Nasdaq Stockholm (STO) under a harmonized listing structure.
Michel Demaré, Chair of AstraZeneca, stated that this marks the start of a new period for AstraZeneca, providing broader access to the largest capital market globally. This allows more investors to participate in AstraZeneca’s future. Demaré noted that the harmonized listing across New York, London, and Stockholm reflects shareholder support for their growth strategy and positions AstraZeneca to deliver more innovative medicines to patients worldwide.
Lynn Martin, President of NYSE Group, welcomed AstraZeneca to the NYSE, emphasizing that the company joins a community of groundbreakers and industry leaders. Martin believes that through its listing on the world’s largest and most liquid capital market, AstraZeneca is well-positioned to expand its global investor base and accelerate its commitment to delivering innovation to the biopharmaceutical industry.
AstraZeneca’s growth is driven by its global reach and diverse sources of business. The previous year included new pipeline readouts representing a peak revenue opportunity exceeding $10 billion. Building on this momentum into 2026, the company is confident in reaching its 2030 ambition to grow annual revenue to $80 billion and launch 20 new medicines. Beyond 2030, AstraZeneca is investing in transformative technologies to change the practice of medicine across its portfolio.
AstraZeneca ordinary shares will continue to trade under the ticker symbol “AZN” across the three exchanges. The company’s listing in the UK on the LSE and in Sweden on the STO remain unaffected and are included in the FTSE 100 and OMX Stockholm 30 indices.
The prior listing of American Depositary Shares and U.S. dollar bonds issued by the company and AstraZeneca Finance LLC (AstraZeneca US Bonds) on Nasdaq in the U.S. ceased on January 30, 2026. Trading of the AstraZeneca US Bonds on the NYSE will commence immediately following the start of trading of the ordinary shares on the NYSE.
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Headquartered in Cambridge, UK, AstraZeneca’s medicines are sold in over 125 countries and used by millions of patients.
Source: AstraZeneca
